CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

which involves introducing a functional copy of the faulty gene into the patient’s cells, thereby encouraging the production of factor IX in the body. This revolutionary approach not only improves ...

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

Fidanacogene elaparvovec is a novel, investigational vector containing a bio-engineered adeno-associated virus capsid and a high-activity human coagulation factor IX gene. A lack of the gene ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Ridecell, a global leader in fleet orchestration solutions, today announced the results of a survey which gathered insights from senior leaders across banks and captive finance companies, to identify ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a ...